ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag drug manufacturing neuroscience microbiology

A rendering of a human brain in blue on a dark background with blue and white lines surrounding the brain to represent the construction of new connections in the brain.
Defying Dogma: Decentralized Translation in Neurons
Danielle Gerhard, PhD | Sep 8, 2023 | 10+ min read
To understand how memories are formed and maintained, neuroscientists travel far beyond the cell body in search of answers.
illustration of neurons in blue with synapses lighting up
Gut Molecule Linked to Decreased Myelination in Mouse Brains
Angie Voyles Askham, Spectrum | Feb 17, 2022 | 4 min read
A study shows that a molecule produced by intestinal microbes can enter the brain and that its presence is also associated with altered brain connectivity.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Those We Lost in 2019
Ashley Yeager | Dec 30, 2019 | 6 min read
The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.
Of Cells and Limits
Anna Azvolinsky | Mar 1, 2015 | 9 min read
Leonard Hayflick has been unafraid to speak his mind, whether it is to upend a well-entrenched dogma or to challenge the federal government. At 86, he’s nowhere near retirement.
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
A Weighty Matter: Neuropeptides Involved In Appetite And Energy Homeostasis
Deborah Wilkinson | Sep 12, 1999 | 10+ min read
Date: September 13, 1999Table of Neurochemical Manufacturers The hypothalamus has long been known as a control center for feeding and weight control behaviors. Complex regulatory feedback loops enable this portion of the brain to determine satiety and metabolic activity. Not surprisingly, the control mechanisms are complex and involve different biochemical pathways.1,2,3 Image courtesy of Jeffrey M. Friedman An ob/ob mouse stacking up against its lean counterparts A series of pioneering expe

Run a Search

ADVERTISEMENT